GentiBio, Inc
Boston
MA
United States
12 articles about GentiBio, Inc
-
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they've done to earn their place on the list - and what's on the horizon. -
GentiBio Announces Preclinical Data Showing Antigen Specific Engineered Tregs Suppressing Pancreatic Inflammation and Potential Utility for Treatment and Prevention of Clinical Type 1 Diabetes (T1D)
10/11/2022
GentiBio, Inc., a biotherapeutics company developing engineered T regulatory (Treg) cells (EngTregs) therapies for autoimmune, auto-inflammatory, alloimmune and allergic diseases, today announced the release of preclinical data demonstrating a novel approach for using engineered Tregs to potentially treat and prevent type 1 diabetes (T1D).
-
GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases
9/14/2022
GentiBio, Inc., a biotherapeutics company developing engineered T regulatory (Treg) cells (EngTregs) therapies for autoimmunity, autoinflammation and allergic diseases, today announced an upcoming presentation of preclinical data relating to the company's platform technology.
-
GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases
8/10/2022
GentiBio, Inc., an engineered regulatory T cells (Tregs) company, announced today that it has entered into a collaboration with Bristol Myers Squibb to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD).
-
In partnership with GentiBio, BMS aims to harness the capabilities of engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with IBD. -
GentiBio Announces Participation in Two Upcoming Investor Conferences
6/23/2022
GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cell (Tregs) therapies for autoimmunity, autoinflammation and allergic diseases, today announced that the company will participate in two upcoming investor conferences.
-
GentiBio Appoints Neely Mozaffarian, MD, PhD as Chief Medical Officer
6/1/2022
GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells therapies for autoimmunity, autoinflammation and allergic diseases, announced that Neely Mozaffarian, M.D., Ph.D., has been appointed to the position of Chief Medical Officer.
-
GentiBio Appoints Industry Veteran Chuck Silberstein as Chief Financial Officer
2/10/2022
GentiBio, Inc. today announced the appointment of Chuck Silberstein , M.D., MBA, as Chief Financial Officer (CFO).
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace. -
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between. -
Inflammation is an important protective mechanism if it can be controlled. This is a key component of Genti’s engineering and the secret to the potency of its Tregs.